Researchers have combined artificial intelligence with molecular pharmacology to identify Bufalin as a novel molecular glue degrader targeting estrogen receptor alpha (ERα), a key driver in hormone-responsive cancers. This AI-driven discovery, reported in Nature Communications, exemplifies the accelerating impact of computational methods in drug discovery, particularly for challenging molecular targets in oncology.